Núria Galeano-Dalmau
AstraZeneca (United Kingdom)(GB)AstraZeneca (Singapore)(SG)
Publications by Year
Research Areas
Esophageal Cancer Research and Treatment, Gastric Cancer Management and Outcomes, Prostate Cancer Treatment and Research, Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics
Most-Cited Works
- → Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance(2016)431 cited
- → Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics(2018)330 cited
- → Risk stratification of Barrett's oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study(2016)122 cited
- → Methylation panel is a diagnostic biomarker for Barrett’s oesophagus in endoscopic biopsies and non-endoscopic cytology specimens(2017)100 cited
- → HES6 drives a critical AR transcriptional programme to induce castration‐resistant prostate cancer through activation of an E 2 F 1‐mediated cell cycle network(2014)84 cited
- → Selection and Application of Tissue microRNAs for Nonendoscopic Diagnosis of Barrett’s Esophagus(2018)43 cited
- → A biomarker panel predicts progression of Barrett's esophagus to esophageal adenocarcinoma(2018)29 cited
- → Application of a multi‐gene next‐generation sequencing panel to a non‐invasive oesophageal cell‐sampling device to diagnose dysplastic Barrett's oesophagus(2017)12 cited
- → Erratum: Corrigendum: Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance(2017)7 cited
- → Discovery of AZD9750, an Orally Bioavailable Androgen Receptor Degrader for the Treatment of Prostate Cancer(2026)